Please assess the completion status of the following clinical trial:

Trial Title: Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic, or acute liver disease~* Rapidly progressive reduction in renal function, e.g. doubling of serum creatinine to \>2.5 mg/dL in less than two weeks.~* No sustained improvement in renal function after diuretic withdrawal and plasma volume expansion~* Proteinuria \<500 mg per day~* No evidence of granular casts in urinalysis or ultrasonographic evidence of obstructive uropathy or parenchymal renal disease~Exclusion Criteria:~* Ongoing shock~* Uncontrolled bacterial infection~* Current significant fluid losses~* Current or recent treatment with nephrotoxic drugs (e.g. NSAIDs or aminoglycosides within 4 weeks)~* Acute liver disease due to factors known to be also directly nephrotoxic (e.g. acetaminophen overdose)~* Confirmed pregnancy~* Severe cardiovascular disease~* Evidence of intrinsic or parenchymal renal disease (e.g. acute tubular necrosis)~* Participation in other clinical studies within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin (Type: EXPERIMENTAL): Terlipressin
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).